Nobuaki Kobayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nobuaki Kobayashi has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Kaneko
41 shared publicationsMakoto Kudo
Department of Pulmonology, Yokohama City University Medical Center, Yokohama, Japan
22 shared publicationsSousuke Kubo
22 shared publicationsYu Hara
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
21 shared publicationsKeisuke Watanabe
Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
20 shared publications- Nobuyuki Horita
Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan
20 shared publications
Latest Publications
- 23 October 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (6)
Acceptability of a web-based decision aid for early-stage non-small cell lung cancer treatment selection: A prospective pilot study
- 23 October 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (6)
Acceptability of a web-based decision aid for early-stage non-small cell lung cancer treatment selection: A prospective pilot study
- Open Access
- 14 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (33) , e50249
Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy
Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC). However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenase-to-lymphocyte ratio (LLR) is a potential indicator of tumor metabolism and host immune response; a high LLR is correlated with a poor prognosis in other carcinomas. The LLR may be a more comprehensive indicator of prognosis than the neutrophil-lymphocyte ratio (NLR) or platelet-lymphocyte ratio (PLR), which mainly reflect host immune status. This study evaluates the prognostic value of the LLR in patients with SCLC receiving first-line chemoimmunotherapy. This retrospective, two-center study was conducted at 2 university hospitals in Japan and analyzed 64 patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limited-stage SCLC who received platinum-etoposide plus a PD-L1 inhibitor as first-line therapy between August 2019 and December 2023. The LLR, NLR, and PLR were calculated from blood tests immediately before the start of first-line therapy, and cutoff values were set using the X-tile software. The prognostic significance of these markers was assessed using Kaplan–Meier survival analysis and the Cox proportional hazards model. Of the 64 patients included, 10 (16%) had high LLR (>471.5). The median duration of observation was 10.5 months (interquartile range: 6.0–19.0 months); by the time of data cutoff, 56 patients (87.5%) had experienced progressive disease and 36 (56.3%) had died. The high LLR group had significantly shorter overall survival (OS) and progression-free survival (PFS). Multivariate analysis was performed using only those factors (LLR/ECOG PS/bone metastasis regarding OS and LLR/bone metastasis regarding PFS) identified as significant in univariate analyses. A high LLR was an independent predictor of worse OS and PFS. While the NLR was an independent prognostic factor for OS, neither NLR nor PLR was a significant predictor of PFS. The LLR is a novel potential prognostic biomarker that integrates tumor metabolism and host immunity in patients with SCLC receiving first-line chemoimmunotherapy. Because it can be readily calculated from routine blood tests, it may serve as a cost-effective tool for risk stratification. However, further prospective validation in larger cohorts is warranted.
- 14 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (33) , e50249
Open AccessLactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy
Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC). However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenase-to-lymphocyte ratio (LLR) is a potential indicator of tumor metabolism and host immune response; a high LLR is correlated with a poor prognosis in other carcinomas. The LLR may be a more comprehensive indicator of prognosis than the neutrophil-lymphocyte ratio (NLR) or platelet-lymphocyte ratio (PLR), which mainly reflect host immune status. This study evaluates the prognostic value of the LLR in patients with SCLC receiving first-line chemoimmunotherapy. This retrospective, two-center study was conducted at 2 university hospitals in Japan and analyzed 64 patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limited-stage SCLC who received platinum-etoposide plus a PD-L1 inhibitor as first-line therapy between August 2019 and December 2023. The LLR, NLR, and PLR were calculated from blood tests immediately before the start of first-line therapy, and cutoff values were set using the X-tile software. The prognostic significance of these markers was assessed using Kaplan–Meier survival analysis and the Cox proportional hazards model. Of the 64 patients included, 10 (16%) had high LLR (>471.5). The median duration of observation was 10.5 months (interquartile range: 6.0–19.0 months); by the time of data cutoff, 56 patients (87.5%) had experienced progressive disease and 36 (56.3%) had died. The high LLR group had significantly shorter overall survival (OS) and progression-free survival (PFS). Multivariate analysis was performed using only those factors (LLR/ECOG PS/bone metastasis regarding OS and LLR/bone metastasis regarding PFS) identified as significant in univariate analyses. A high LLR was an independent predictor of worse OS and PFS. While the NLR was an independent prognostic factor for OS, neither NLR nor PLR was a significant predictor of PFS. The LLR is a novel potential prognostic biomarker that integrates tumor metabolism and host immunity in patients with SCLC receiving first-line chemoimmunotherapy. Because it can be readily calculated from routine blood tests, it may serve as a cost-effective tool for risk stratification. However, further prospective validation in larger cohorts is warranted.
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1)
Clinical Impact of HRCT UIP Pattern Among Patients With Idiopathic Pulmonary Fibrosis Undergoing Antifibrotic Treatment: A Multicenter Retrospective Observational Study
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease with a poor prognosis. Honeycombing on high‐resolution computed tomography (HRCT) is a defining feature of the usual interstitial pneumonia (UIP) pattern and has traditionally been considered a marker of advanced disease. However, in the era of antifibrotic treatment (AFT), the prognostic significance of the UIP pattern in IPF remains uncertain. This study aimed to evaluate the association between HRCT UIP pattern and long‐term prognosis in patients with IPF receiving AFT. Methods: This retrospective multicenter study investigated consecutive patients with IPF who initiated AFT between 2009 and 2019 at seven institutions in Japan. HRCT patterns were classified as UIP or non‐UIP by multidisciplinary assessment. The primary outcome was IPF‐related events, defined as IPF‐related death or first acute exacerbation (AE) after initiating AFT. Event‐free survival was analyzed using Kaplan–Meier methods with stratification by gender–age–physiology (GAP) stage. Propensity score matching (PSM) was performed to adjust for age, sex, GAP score, and antifibrotic agent. Results: Of the 139 patients included, 99 had a UIP pattern, and 40 had a non‐UIP pattern. In the overall cohort, event‐free survival did not differ significantly. Stratified analyses showed no significant survival difference between UIP and non‐UIP patterns among GAP Stage I patients (median survival time [MST]: 2050 vs. 1104 days; p = 0.90). Similarly, among patients with GAP Stages II–III, MST did not differ significantly. After PSM, 34 matched pairs were analyzed, and no significant differences in event‐free survival were observed between UIP and non‐UIP patterns. Conclusions: In patients with IPF treated with AFT, the radiological UIP pattern on HRCT was not independently associated with long‐term prognosis. Multidimensional risk assessment incorporating physiological impairment and disease behavior may provide more accurate prognostic stratification in treated UIP populations.
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1)
Open AccessClinical Impact of HRCT UIP Pattern Among Patients With Idiopathic Pulmonary Fibrosis Undergoing Antifibrotic Treatment: A Multicenter Retrospective Observational Study
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease with a poor prognosis. Honeycombing on high‐resolution computed tomography (HRCT) is a defining feature of the usual interstitial pneumonia (UIP) pattern and has traditionally been considered a marker of advanced disease. However, in the era of antifibrotic treatment (AFT), the prognostic significance of the UIP pattern in IPF remains uncertain. This study aimed to evaluate the association between HRCT UIP pattern and long‐term prognosis in patients with IPF receiving AFT. Methods: This retrospective multicenter study investigated consecutive patients with IPF who initiated AFT between 2009 and 2019 at seven institutions in Japan. HRCT patterns were classified as UIP or non‐UIP by multidisciplinary assessment. The primary outcome was IPF‐related events, defined as IPF‐related death or first acute exacerbation (AE) after initiating AFT. Event‐free survival was analyzed using Kaplan–Meier methods with stratification by gender–age–physiology (GAP) stage. Propensity score matching (PSM) was performed to adjust for age, sex, GAP score, and antifibrotic agent. Results: Of the 139 patients included, 99 had a UIP pattern, and 40 had a non‐UIP pattern. In the overall cohort, event‐free survival did not differ significantly. Stratified analyses showed no significant survival difference between UIP and non‐UIP patterns among GAP Stage I patients (median survival time [MST]: 2050 vs. 1104 days; p = 0.90). Similarly, among patients with GAP Stages II–III, MST did not differ significantly. After PSM, 34 matched pairs were analyzed, and no significant differences in event‐free survival were observed between UIP and non‐UIP patterns. Conclusions: In patients with IPF treated with AFT, the radiological UIP pattern on HRCT was not independently associated with long‐term prognosis. Multidimensional risk assessment incorporating physiological impairment and disease behavior may provide more accurate prognostic stratification in treated UIP populations.
- Open Access
The miR-200 Family in Non-Small-Cell Lung Cancer: Molecular Mechanisms, Clinical Applications, and Therapeutic Implications
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, demanding improved biomarkers and therapeutic approaches. This review synthesizes the extensive evidence positioning the miR-200 family as a master regulator of NSCLC progression. We detail the core molecular circuitry centered on the bistable, double-negative feedback loop between miR-200 and the ZEB1/ZEB2 transcription factors, which governs epithelial–mesenchymal transition (EMT). This review connects this central mechanism to critical clinical challenges, including the development of resistance to EGFR-targeted therapies and the regulation of immune evasion through PD-L1 expression and CD8+ T cell infiltration. We evaluate the strong clinical evidence for the miR-200 family’s utility as a diagnostic, prognostic, and predictive biomarker. Finally, we explore emerging therapeutic strategies that target this network, including miRNA replacement, epigenetic reactivation, and rational combinations with immunotherapy and targeted agents. We synthesize evidence positioning the miR-200/ZEB feedback circuit as a central regulatory node in NSCLC that links EMT with therapeutic resistance and immune evasion. Beyond summarizing associations, we interpret how this circuitry could inform biomarker development and rational combinations with targeted and immune therapies. Given heterogeneous study designs and non-standardized assays, translational claims remain provisional; we outline immediate priorities for assay harmonization and biomarker-stratified trials.
Open AccessThe miR-200 Family in Non-Small-Cell Lung Cancer: Molecular Mechanisms, Clinical Applications, and Therapeutic Implications
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, demanding improved biomarkers and therapeutic approaches. This review synthesizes the extensive evidence positioning the miR-200 family as a master regulator of NSCLC progression. We detail the core molecular circuitry centered on the bistable, double-negative feedback loop between miR-200 and the ZEB1/ZEB2 transcription factors, which governs epithelial–mesenchymal transition (EMT). This review connects this central mechanism to critical clinical challenges, including the development of resistance to EGFR-targeted therapies and the regulation of immune evasion through PD-L1 expression and CD8+ T cell infiltration. We evaluate the strong clinical evidence for the miR-200 family’s utility as a diagnostic, prognostic, and predictive biomarker. Finally, we explore emerging therapeutic strategies that target this network, including miRNA replacement, epigenetic reactivation, and rational combinations with immunotherapy and targeted agents. We synthesize evidence positioning the miR-200/ZEB feedback circuit as a central regulatory node in NSCLC that links EMT with therapeutic resistance and immune evasion. Beyond summarizing associations, we interpret how this circuitry could inform biomarker development and rational combinations with targeted and immune therapies. Given heterogeneous study designs and non-standardized assays, translational claims remain provisional; we outline immediate priorities for assay harmonization and biomarker-stratified trials.
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (11) , 9242-9246
Subcutaneous administration of pembrolizumab: a paradigm shift toward patient-centered cancer care
Subcutaneous administration of pembrolizumab: a paradigm shift toward patient-centered cancer care
- 1 November 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (11) , 9242-9246
Open AccessSubcutaneous administration of pembrolizumab: a paradigm shift toward patient-centered cancer care
Subcutaneous administration of pembrolizumab: a paradigm shift toward patient-centered cancer care
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2636-2645
Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study
Background: While immune checkpoint inhibitors (ICIs) have significantly improved outcomes for many non-small cell lung cancer (NSCLC) patients, phase 3 trials have shown limited efficacy in programmed cell death ligand 1 (PD-L1) negative subgroups. This study aimed to evaluate the real-world effectiveness and safety of ICI-containing regimens vs. chemotherapy alone in PD-L1 negative NSCLC patients. Methods: This multicenter, retrospective study analyzed advanced or recurrent NSCLC patients treated between 2015 and 2022 in Japan. From an initial screening of 1,382 patients, we identified patients with PD-L1 negative [tumor proportion score (TPS) Results: Among the 86 eligible patients identified, 54 received ICI-containing regimens (IC group) and 32 received chemotherapy alone (C group). No significant difference in OS (C vs. IC: median 14.9 vs. 23.8 months, P=0.87) and PFS (C vs. IC: median 6.6 vs. 7.8 months, P=0.20) was observed after covariates adjustment. The overall response rate was higher in the IC group (C vs. IC: 34.4% vs. 50.0%), as was the disease control rate (C vs. IC: 65.6% vs. 81.5%). AEs profiles were similar between groups, with grade 3–4 events occurring in 56.2% of C patients and 59.2% of IC patients. Treatment discontinuation rates due to AEs were comparable (C vs. IC: 21.9% vs. 24.1%, P=0.71). Conclusions: In this real-world study of PD-L1 negative NSCLC patients, ICI-containing regimens did not demonstrate significantly improved OS or PFS compared to chemotherapy alone. Limited efficacy in this population highlights the need for further investigation and advancement in treatment strategies.
- 1 July 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2636-2645
Open AccessReal-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study
Background: While immune checkpoint inhibitors (ICIs) have significantly improved outcomes for many non-small cell lung cancer (NSCLC) patients, phase 3 trials have shown limited efficacy in programmed cell death ligand 1 (PD-L1) negative subgroups. This study aimed to evaluate the real-world effectiveness and safety of ICI-containing regimens vs. chemotherapy alone in PD-L1 negative NSCLC patients. Methods: This multicenter, retrospective study analyzed advanced or recurrent NSCLC patients treated between 2015 and 2022 in Japan. From an initial screening of 1,382 patients, we identified patients with PD-L1 negative [tumor proportion score (TPS) Results: Among the 86 eligible patients identified, 54 received ICI-containing regimens (IC group) and 32 received chemotherapy alone (C group). No significant difference in OS (C vs. IC: median 14.9 vs. 23.8 months, P=0.87) and PFS (C vs. IC: median 6.6 vs. 7.8 months, P=0.20) was observed after covariates adjustment. The overall response rate was higher in the IC group (C vs. IC: 34.4% vs. 50.0%), as was the disease control rate (C vs. IC: 65.6% vs. 81.5%). AEs profiles were similar between groups, with grade 3–4 events occurring in 56.2% of C patients and 59.2% of IC patients. Treatment discontinuation rates due to AEs were comparable (C vs. IC: 21.9% vs. 24.1%, P=0.71). Conclusions: In this real-world study of PD-L1 negative NSCLC patients, ICI-containing regimens did not demonstrate significantly improved OS or PFS compared to chemotherapy alone. Limited efficacy in this population highlights the need for further investigation and advancement in treatment strategies.
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2522-2536
MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer
Background: The microRNA (miR)-200 family is implicated in regulating the immune checkpoint protein programmed death-ligand 1 (PD-L1), a key factor in lung cancer progression and response to immunotherapy. This study investigates the relationship between miR-200 expression and PD-L1 in non-small cell lung cancer (NSCLC), aiming to clarify its potential as a prognostic biomarker and a therapeutic target in immune checkpoint inhibitor (ICI) treatment for NSCLC. Methods: RNA sequencing (RNA-seq) data from public databases were analyzed for correlation between miR-200 family expression and PD-L1 levels in lung cancer. MiR-200 and PD-L1 expression were assessed in lung cancer cell lines by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and flow cytometry, respectively. To evaluate functional impact, miR-200 mimics were transfected into cell lines, and PD-L1 protein levels were measured. The influence of interferon gamma (IFN-γ) on miR-200 and PD-L1 expressions in cell lines were examined using RT-qPCR and flow cytometry. Serum samples and tumor biopsies were collected from advanced NSCLC patients before ICI therapy. Serum miR-200a was quantified by Droplet digital polymerase chain reaction (ddPCR), and its correlation with tumor PD-L1 and progression-free survival (PFS) was analyzed. Results: Analysis of RNA-seq data revealed a significant inverse correlation between miR-200 family expression and PD-L1 levels in lung cancer (Pvs. miR-200a-low, 200 days; P=0.008). Conclusions: This study shows that miR-200a regulates PD-L1 expression in NSCLC, affecting immune evasion. Serum miR-200a levels could serve as a non-invasive biomarker to predict PD-L1 expression and immunotherapy outcomes, helping identify patients who may benefit. Modulating miR-200a may also offer a new strategy to reduce PD-L1 in tumors, enhancing immune response.
- 1 July 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2522-2536
Open AccessMiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer
Background: The microRNA (miR)-200 family is implicated in regulating the immune checkpoint protein programmed death-ligand 1 (PD-L1), a key factor in lung cancer progression and response to immunotherapy. This study investigates the relationship between miR-200 expression and PD-L1 in non-small cell lung cancer (NSCLC), aiming to clarify its potential as a prognostic biomarker and a therapeutic target in immune checkpoint inhibitor (ICI) treatment for NSCLC. Methods: RNA sequencing (RNA-seq) data from public databases were analyzed for correlation between miR-200 family expression and PD-L1 levels in lung cancer. MiR-200 and PD-L1 expression were assessed in lung cancer cell lines by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and flow cytometry, respectively. To evaluate functional impact, miR-200 mimics were transfected into cell lines, and PD-L1 protein levels were measured. The influence of interferon gamma (IFN-γ) on miR-200 and PD-L1 expressions in cell lines were examined using RT-qPCR and flow cytometry. Serum samples and tumor biopsies were collected from advanced NSCLC patients before ICI therapy. Serum miR-200a was quantified by Droplet digital polymerase chain reaction (ddPCR), and its correlation with tumor PD-L1 and progression-free survival (PFS) was analyzed. Results: Analysis of RNA-seq data revealed a significant inverse correlation between miR-200 family expression and PD-L1 levels in lung cancer (Pvs. miR-200a-low, 200 days; P=0.008). Conclusions: This study shows that miR-200a regulates PD-L1 expression in NSCLC, affecting immune evasion. Serum miR-200a levels could serve as a non-invasive biomarker to predict PD-L1 expression and immunotherapy outcomes, helping identify patients who may benefit. Modulating miR-200a may also offer a new strategy to reduce PD-L1 in tumors, enhancing immune response.
- Open Access
- 1 February 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (2) , 353-362
Rapid detection of non-small cell lung cancer driver mutations using droplet digital polymerase chain reaction analysis of bronchial washings: a prospective multicenter study
Background: Molecular profiling of non-small cell lung cancer (NSCLC) is crucial for personalized treatment, but obtaining adequate tumor tissue can be challenging. This study evaluated the utility of droplet digital polymerase chain reaction (ddPCR) analysis of bronchial washings (BWs) and serum for detecting driver oncogene mutations in NSCLC patients, comparing its performance to standard tissue genotyping methods. Methods: In this prospective, multicenter study conducted at two university hospitals in Yokohama, Japan, 73 treatment-naïve NSCLC patients underwent bronchoscopy with BW collection and blood sampling between October 2022 and April 2024. ddPCR was performed on BW and serum samples to detect epidermal growth factor receptor (EGFR; L858R, exon 19 deletions, G719X), KRAS (G12/13), and BRAF (V600E) mutations. Results were compared with standard tissue genotyping methods, including AmoyDx and Oncomine Dx Target Test (DxTT) assays. Turnaround time (TAT) for results was also assessed. The study protocol was approved by the institutional review boards, and all participants provided informed consent. Results: ddPCR analysis of BW samples showed high concordance with tissue genotyping, detecting EGFR mutations in 31.5% of cases (identical to tissue). For common EGFR mutations (L858R and exon 19 deletions), BW genotyping demonstrated 100% sensitivity and 98.0% specificity compared to tissue. TAT was significantly shorter for BW ddPCR compared to tissue genotyping (4.4±1.8 vs. 20.4±7.7 days, Pvs. 33.3% for EGFR mutations) compared to tissue genotyping, with detection associated with the presence of bone metastases. KRAS and BRAF mutations were detected at similar rates in BW and tissue samples, but at lower rates in serum. Conclusions: ddPCR analysis of BWs demonstrates high accuracy and rapid TAT for detecting common driver mutations in NSCLC. This approach represents a promising alternative to tissue biopsy for molecular profiling, potentially expediting treatment decisions. While serum ddPCR showed limited utility, it may complement tissue genotyping in specific clinical scenarios.
- 1 February 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (2) , 353-362
Open AccessRapid detection of non-small cell lung cancer driver mutations using droplet digital polymerase chain reaction analysis of bronchial washings: a prospective multicenter study
Background: Molecular profiling of non-small cell lung cancer (NSCLC) is crucial for personalized treatment, but obtaining adequate tumor tissue can be challenging. This study evaluated the utility of droplet digital polymerase chain reaction (ddPCR) analysis of bronchial washings (BWs) and serum for detecting driver oncogene mutations in NSCLC patients, comparing its performance to standard tissue genotyping methods. Methods: In this prospective, multicenter study conducted at two university hospitals in Yokohama, Japan, 73 treatment-naïve NSCLC patients underwent bronchoscopy with BW collection and blood sampling between October 2022 and April 2024. ddPCR was performed on BW and serum samples to detect epidermal growth factor receptor (EGFR; L858R, exon 19 deletions, G719X), KRAS (G12/13), and BRAF (V600E) mutations. Results were compared with standard tissue genotyping methods, including AmoyDx and Oncomine Dx Target Test (DxTT) assays. Turnaround time (TAT) for results was also assessed. The study protocol was approved by the institutional review boards, and all participants provided informed consent. Results: ddPCR analysis of BW samples showed high concordance with tissue genotyping, detecting EGFR mutations in 31.5% of cases (identical to tissue). For common EGFR mutations (L858R and exon 19 deletions), BW genotyping demonstrated 100% sensitivity and 98.0% specificity compared to tissue. TAT was significantly shorter for BW ddPCR compared to tissue genotyping (4.4±1.8 vs. 20.4±7.7 days, Pvs. 33.3% for EGFR mutations) compared to tissue genotyping, with detection associated with the presence of bone metastases. KRAS and BRAF mutations were detected at similar rates in BW and tissue samples, but at lower rates in serum. Conclusions: ddPCR analysis of BWs demonstrates high accuracy and rapid TAT for detecting common driver mutations in NSCLC. This approach represents a promising alternative to tissue biopsy for molecular profiling, potentially expediting treatment decisions. While serum ddPCR showed limited utility, it may complement tissue genotyping in specific clinical scenarios.
- Open Access
The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids
Objectives: This research aims to investigate the mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC), particularly focusing on the role of the epithelial–mesenchymal transition (EMT) within the tumor microenvironment (TME). Materials and Methods: We employed an in vitro three-dimensional organoid model that mirrors the physiology of human lung cancer. These organoids consist of lung cancer cells harboring specific EGFR mutations, human mesenchymal stem cells, and human umbilical vein endothelial cells. We analyzed EMT and drug resistance markers, and evaluated the effects of the anti-angiogenic agent Bevacizumab and micro-RNA miR200c. Results: The study identified a significant link between EMT and EGFR-TKI resistance. Notable findings included a decrease in E-cadherin and an increase in Zinc Finger E-Box Binding Homeobox 1 (ZEB1), both of which influenced EMT and resistance to treatment. Bevacizumab showed promise in improving drug resistance and mitigating EMT, suggesting an involvement of the Vascular Endothelial Growth Factor (VEGF) cascade. Transfection with miR200c was associated with improved EMT and drug resistance, further highlighting the role of EMT in TKI resistance. Conclusions: Our research provides significant insights into the EMT-driven EGFR-TKI resistance in NSCLC and offers potential strategies to overcome resistance, including the use of Bevacizumab and miR200c. However, due to the limitations in organoid models in replicating precise human cancer TME and the potential influence of specific EGFR mutations, further in vivo studies and clinical trials are necessary for validation.
Open AccessThe Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids
Objectives: This research aims to investigate the mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC), particularly focusing on the role of the epithelial–mesenchymal transition (EMT) within the tumor microenvironment (TME). Materials and Methods: We employed an in vitro three-dimensional organoid model that mirrors the physiology of human lung cancer. These organoids consist of lung cancer cells harboring specific EGFR mutations, human mesenchymal stem cells, and human umbilical vein endothelial cells. We analyzed EMT and drug resistance markers, and evaluated the effects of the anti-angiogenic agent Bevacizumab and micro-RNA miR200c. Results: The study identified a significant link between EMT and EGFR-TKI resistance. Notable findings included a decrease in E-cadherin and an increase in Zinc Finger E-Box Binding Homeobox 1 (ZEB1), both of which influenced EMT and resistance to treatment. Bevacizumab showed promise in improving drug resistance and mitigating EMT, suggesting an involvement of the Vascular Endothelial Growth Factor (VEGF) cascade. Transfection with miR200c was associated with improved EMT and drug resistance, further highlighting the role of EMT in TKI resistance. Conclusions: Our research provides significant insights into the EMT-driven EGFR-TKI resistance in NSCLC and offers potential strategies to overcome resistance, including the use of Bevacizumab and miR200c. However, due to the limitations in organoid models in replicating precise human cancer TME and the potential influence of specific EGFR mutations, further in vivo studies and clinical trials are necessary for validation.
- Open Access
- 22 November 2024
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 37, 100497
Dissecting regional variability in Pyrazinamide prescribing practices for tuberculosis treatment in Japan
- 22 November 2024
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 37, 100497
Open AccessDissecting regional variability in Pyrazinamide prescribing practices for tuberculosis treatment in Japan